AIT Therapeutics has obtained a funding agreement that will raise $8 million through private investment in public equity (PIPE) financing…
Articles by Patricia Inácio, PhD
AIT Therapeutics’ on-demand nitric oxide (NO) ventilator is safer for patients with pulmonary hypertension (PH), and for…
The Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, recently launched by Bayer US, will grant up to $1 million dollars for…
Survival rates of patients with chronic thromboembolic pulmonary hypertension (CTEPH) unable to undergo surgical treatment have significantly improved in…
Certain parameters of poor heart function are risk factors for early death among idiopathic pulmonary arterial hypertension (IPAH) patients who…
Levels of NT-proBNP can predict long-term outcomes and response to treatment with Uptravi (selexipag) in patients with pulmonary arterial hypertension (PAH),…
Despite having better heart function and less severe disease, patients with a lung disease underlying their pulmonary hypertension (PH) have…
United Therapeutics announced it has ended its Phase 3 BEAT trial testing esuberaprost as an add-on therapy to its product …
Mutations in the BMPR2 gene alter the ratio of pro- and anti-death signals in cells lining the blood vessels, promoting cells…
People with polysplenia syndrome — a condition characterized by a “left-sidedness” on both sides of the body — have an…
Estrogen, one of the major female sex hormones, has a protective effect in pulmonary arterial hypertension (PAH) by halting…
High pulmonary pressure, cardiac medication use, and poor heart function are all risk factors for pulmonary hypertension (PH) in…